Healthcare Solutions Company Receives Initial Order for Ophthalmic Diagnostic Tests and Readers, Marking First Large Revenue Generating Order for Company
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has received an initial order of 19,000 point-of-care (POC) diagnostic tests and 100 readers targeting ocular surface diseases through its exclusive global commercialization partner Verséa Ophthalmics, LLC (“Verséa”), marking the Company’s first large-scale revenue generating order.
The order is part of the recently announced exclusive global commercialization agreement reached between Verséa and AXIM to support the commercial launch of sales at the 2022 American Academy of Ophthalmology (AAO) conference in Chicago. The order represents the largest revenue-generating event in the history of the Company. AXIM has successfully completed manufacturing and is preparing the order for shipment from its lab facilities in San Diego, California as per Verséa’s direction. The order includes both the tear based tests for Lactoferrin and Immunoglobulin E (IgE) as well as the associated digital reader that allows for quantitative test results. The tests provide doctors with access to real-time quantitative results within 10 minutes, allowing them to more accurately diagnose and prescribe targeted therapy to patients, leading to overall improved personalized patient care. Both tests are FDA-cleared and have dedicated Medicare CPT codes that allow for rapid POC diagnosis of common ocular conditions such as dry eye disease (DED) and allergic conjunctivitis.
“This large order through our agreement with Verséa Ophthalmics marks a pivotal point for AXIM, where we are not only revenue generating, but we will soon boast that our tests and readers are available in over 100 clinics nationwide – a true testament to the quality of our diagnostic platform and the strength of Verséa as our commercial partner,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “Even more exciting is the fact that this is just the initial order through Verséa. While our readers can be used over and over again, our test strips are one-time use and should this initial deployment of our tests go well, we expect to receive repeat orders from clinicians who have performed the tests and for this to be additive to the growing new test demand. I could not be more proud of our scientific team for their hard work in developing these diagnostic tools as well as delighted with our newly minted relationship with Verséa.”
“We are extremely optimistic about the initial reception seen with our launch of the ocular surface disease testing platform and hope that this is just the beginning of a robust testing pipeline of future diagnostic test solutions that can be introduced on the same digital reader system,” said Rob Sambursky, MD President of Verséa Holdings, Inc. and Verséa Ophthalmics, LLC. “Eye care professionals have struggled with differentiating mild allergic conjunctivitis from dry eye disease as well as distinguishing between different causes of dry eye [aqueous deficient versus evaporative] which impacts clinical decision making. The portfolio of rapid, tear-based, quantitative point of care tests allows for more specific diagnoses, targeted therapeutic intervention and the potential for therapeutic monitoring which is a true breakthrough for the industry.”
For more information on the tests or to speak with a member of the Verséa team on carrying the diagnostic tools, please contact ophthalmics@versea.com.
About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit www.AXIMBiotech.com.
About Verséa Holdings, Inc. Verséa Ophthalmic, LLC (“Verséa”), a subsidiary of Verséa Holdings, Inc. headquartered in Tampa, FL, is a U.S. healthcare company founded by experienced business executives and prominent scientific medical experts, all committed to transforming scientific discoveries into applicable healthcare and wellness solutions that are critical to improving patients’ lives. To learn more, visit: www.versea.com.
Forward-Looking Statements The statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Further, Axim’s eye care diagnostic products that are FDA cleared may not be manufactured in large enough quantities or that third parties with established eye care physicians will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2022, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
CONTACT Kyle Porter CMW Media P. 858-221-8001 axim@cmwmedia.com
AXIM Corporate 6191 Cornerstone Ct., Ste. 114 San Diego, CA 92121, USA P. 858-923-4422
Investor Relations investors@aximbiotech.com 888-759-0844
After a failed attempt to broaden the use of its only approved drug, Rigel Pharmaceuticals Inc. will cut 30 jobs — about 16% of its workforce — to save as much as $8 million starting next year. The 200-employee South San Francisco company (NASDAQ: RIGL) made the move as it announced it will not seek Food and Drug Administration approval of its tablet drug fostamatinib based on a reanalysis of data from a late-stage clinical trial. The drug, sold as Tavalisse, is approved by the FDA for an excessive bruising and bleeding disorder known as immune thrombocytopenia, or ITP.
Select Medical (SEM) joins forces with UPMC to open its third inpatient rehabilitation hospital in Central Pennsylvania to better address the region's post-acute care needs.
The company hopes the drug, sotatercept, will help make up for revenue it will lose when the patent on a blockbuster cancer therapeutic expires at the end of this decade.
Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
If you're 65 or older, then Medicare is there to help you get the healthcare coverage you need. For hospital and inpatient care, Medicare Part A is the choice that tens of millions of people turn to. But for covering routine doctor visits and other outpatient care, Medicare Part B is the traditional option for many participants in the program.
“We don’t even know how long that has been happening, or if anybody else is going through it,” family of the injured grandpa said.
The reelection campaign for Gov. Ron DeSantis is out with a new ad highlight how his wife's battle with breast cancer shows a more human side of the Florida Republican.
With their gorgeous blue hue and satisfyingly sweet taste, blueberries are one fruit many people can agree is a welcomed addition to their meals, snacks, and fruity cocktails or mocktails. And as a registered dietitian, I can certainly get behind the goal of eating blueberries every day. The benefits of blueberries are plenty: Between the natural fiber these beautiful blebs contain, the sweet taste they provide with no added sugar, and the boost of antioxidants they naturally house, as a clinici
A new medical study questions the effectiveness of colonoscopies in preventing cancer deaths. CBS News' chief medical correspondent Dr. Jon LaPook explains the study's findings.
Here’s how Arians established a game plan to manage his heart health, and why he’s encouraging others to do the same.
By Mark Gilman -- Benzinga
After Uganda’s outbreak, the CDC urges doctors to be on alert for Ebola—also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF)—a rare but deadly virus.
“The long delay in receiving Medicaid approval for her gender affirming surgery has made TB very mentally fragile, and I am afraid she will once again lose hope and attempt to take her life,” a parent said.
For seniors with chronic medical conditions, a difference in geography could mean paying thousands more per year out-of-pocket for the same medicine.
Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.
Florida Surgeon General Dr. Joseph Ladapo on Friday announced new guidance advising against COVID-19 mRNA vaccines for men aged 18-39, citing a Florida Department of Health study that some have said relies on imperfect data and does little to explain its methodology.
DOCTORS AND MIDWIVES IN BLUE STATES ARE WORKING TO GET ABORTION PILLS INTO RED STATES — SETTING THE STAGE FOR A HISTORIC LEGAL CLASH. When Linda Prine learned she was pregnant in 1970, she was a first-year college student in Wisconsin, where abortion was largely illegal. The doctor who gave her the news saw the look on Prine’s face and handed her a slip of paper with a phone number. Prine waited until other students in her dorm left for class to call from a phone in the hallway. The woman she sp
Worried about Alzheimer's disease? And how can you tell Alzheimer's from normal memory loss? Here are 5 key pieces of information you need to know right now.
A new study from Europe has found that the benefits of regular colonoscopies in helping reduce the risk of colorectal cancer and death may have been overestimated due to gaps in evidence. The Nordic-European Initiative on Colorectal Cancer (NordICC) conducted a trial involving nearly 85,000 people between ages 55 and 64. The study sample included…
Joe Biden committed to taking specific actions related to cannabis in his 2020 presidential campaign. On Thursday, President Biden announced pardons for all individuals with prior federal convictions for simple possession of marijuana. Biden also directed Attorney General Merrick Garland and Secretary of Health and Human Services (HHS) Xavier Becerra to review how marijuana is scheduled under the Controlled Substances Act.